From Amylin Resurrects Obesity Drug, in New Combination with Diabetes Drug Symlin:

amylin1
amylin1—

Amylin Pharmaceuticals is developing drugs for obesity and diabetes

Xconomy’s Most Popular

  1. Don’t Panic, But We’ve Passed Peak Apple. And Google. And Facebook.
  2. With Big Bucks Chasing Big Data, Will Consumers Get a Cut?
  3. Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian
  4. 11 Reasons Why Flickr, Not Facebook, Is the Place to Put Your Photos
  5. Digital Lumens, Finding Its Identity, Brings Cost & Energy Savings to Light

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.